Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 10/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 4/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | FECH | P22830 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838408 | 1.00 | GCK (0.49) | GCKKCNH2NOTUMKLK7IDO1 | |
| SCHEMBL839979 | 0.88 | GCK (0.49) | GCKKCNH2 | |
| SCHEMBL839980 | 0.88 | GCK (0.49) | GCKKCNH2 | |
| SCHEMBL838319 | 0.85 | GCK (0.43) | GCKKCNH2NOTUMCHEK1 | |
| SCHEMBL838320 | 0.85 | GCK (0.43) | GCKKCNH2NOTUMCHEK1 | |
| SCHEMBL839684 | 0.83 | GCK (0.46) | GCKKCNH2NOTUMKLK7IDO1 | |
| SCHEMBL837866 | 0.83 | GCK (0.46) | GCKKCNH2NOTUMIDO1 | |
| SCHEMBL839683 | 0.83 | GCK (0.46) | GCKKCNH2NOTUMKLK7IDO1 | |
| SCHEMBL837867 | 0.83 | GCK (0.46) | GCKKCNH2NOTUMIDO1 | |
| SCHEMBL839612 | 0.80 | GCK (0.48) | GCKKCNH2NOTUMIDO1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | GCK 1/4885KCNH2 1438/4885NOTUM 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.